Mirum Pharmaceuticals (MIRM) just reported that its Phase 3 AZURE-4 trial of brelovitug for chronic hepatitis delta virus met its primary endpoint, with both efficacy and safety outcomes supporting a ...
Source LinkMirum Pharmaceuticals (MIRM) just reported that its Phase 3 AZURE-4 trial of brelovitug for chronic hepatitis delta virus met its primary endpoint, with both efficacy and safety outcomes supporting a ...
Source Link
Comments